Results 1 to 10 of about 3,955 (172)

Current status of cytokine-induced killer cells and combination regimens in breast cancer. [PDF]

Front Immunol
Jiang Y, Qiu J, Ye N, Xu Y.
europepmc   +1 more source

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma. [PDF]

Front Immunol
Moser LM, Heim C, Koschade SE, Wendel P, Bozkurt S, Harenkamp S, Kreyenberg H, Merker M, Münch C, Gradhand E, Vogler M, Ullrich E, Bönig H, Klusmann JH, Bader P, Wels WS, Rettinger E.   +16 more
europepmc   +1 more source

Adoptive cell therapy for cancer: combination strategies and biomarkers. [PDF]

Front Immunol
Liu S, Jiang W, Sheng J, Wang L, Cui M.
europepmc   +1 more source

Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)

Journal of Cancer Research and Clinical Oncology, 2010
Recently, a subset of natural killer T lymphocytes termed "cytokine-induced killer (CIK) cells" has been described. To build an international registry, we collected the clinical data and treatment of patients with cancer using CIK cells from the literature and the respective investigators.
I G H Schmidt-Wolf, Schmidt-Wolf I G H
exaly   +3 more sources

CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma

Cancer Immunology, Immunotherapy, 2020
Adjuvant cytokine-induced killer (CIK) cell immunotherapy has shown potential in improving the prognosis of hepatocellular carcinoma (HCC) patients after curative resection. However, whether an individual could obtain survival benefit from CIK cell treatment remains unknown. In the present study, we focused on the characteristics of CIK cells and aimed
Qing Liu, Jian-Chuan Xia, Qiu-Zhong Pan   +2 more
exaly   +3 more sources

DC-CIK as a widely applicable cancer immunotherapy

Expert Opinion on Biological Therapy, 2020
Introduction: Immunotherapy is now a standard treatment for many malignancies. Although immune checkpoint inhibition has demonstrated substantial efficacy by enhancing T cell activation and function in the tumor microenvironment, adoptive transfer of T and NK cell products promises to provide activated cells capable of immediate and direct tumor ...
Jun Ren, Shuo Wang, Herbert Kim Lyerly
exaly   +3 more sources

Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC)

Journal of Cancer Research and Clinical Oncology, 2014
Cytokine-induced killer (CIK) cells represent an exceptional T cell population uniting a T cell and natural killer cell like phenotype in their terminally differentiated CD3(+)CD56(+) subset, which features non-MHC-restricted tumor-killing activity. CIK cells are expandable from peripheral blood mononuclear cells and mature following the addition of ...
Leonard Christopher Schmeel, Frédéric Schmeel, Schmidt-Wolf Ingo G H   +2 more
exaly   +3 more sources

Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms

Immunology Letters, 2013
Cytokine Induced Killer (CIK) cells are in vitro activated human CD8 T cells which have maintained several characteristics of T-EMRA cells and additionally acquired non specific anti tumoral cytotoxicity and CD56 overexpression, thus representing a cell population with double T and NK phenotype.
Martino Introna, Alessandro Rambaldi, Josée Thérèse Golay   +2 more
exaly   +3 more sources

New adoptive immunotherapy strategies for solid tumours with CIK cells

Expert Opinion on Biological Therapy, 2012
Despite development and introduction of new and innovative drugs, a large number of malignant diseases are associated with unfavourable prognosis. In recent years, considerable progress in cancer treatment has been obtained by the application of cytokine-induced killer (CIK) cells.This review provides an overview and summary of recent advances in ...
Amit Sharma
exaly   +3 more sources